Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-22-2026-05_46_48-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Other
  • 223: An Interview With Dr. Antn Blatnik on the Molecular Mechanisms Driving Neuromuscular Disease
  • Other

223: An Interview With Dr. Antn Blatnik on the Molecular Mechanisms Driving Neuromuscular Disease

Rare Disease Audio

Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Antn Blatnik, PhD, who recently won a $150,000 grant from Cure SMA to study the molecular mechanisms that drive neuromuscular d

Neuroscience

Read full story

pharminent May 4, 2026 (Last updated: May 4, 2026)

Rare Disease Audio

Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Antn Blatnik, PhD, who recently won a $150,000 grant from Cure SMA to study the molecular mechanisms that drive neuromuscular d

Neuroscience

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Eli Lilly to Acquire Kelonia Therapeutics
Next: Celcuity strengthens case for ASCO-spotlighted breast cancer drug

Related Stories

  • Other

ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer

pharminent June 2, 2026
  • Other

ASCO26: Symptom-tracking app helps advanced cancer patients

pharminent June 2, 2026
  • Other

All eyes on Revolution, bispecific antibodies and more at ASCO26

pharminent May 26, 2026

You May Have Missed

  • News

pharminent June 22, 2026
sample_feature_2026-06-22
  • News

AbbVie to Acquire Apogee Therapeutics for Nearly $11 Billion in Immunology Bet

pharminent June 22, 2026
  • M&A / Deals

AbbVie climbs post-Allergan M&A peak with Apogee buy

pharminent June 22, 2026
  • M&A / Deals

Lilly bets up to $800M for BioArctic’s brain delivery tech

pharminent June 22, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.